Reverb Therapeutics Debuts Its Amplifier™ Platform for Redirecting Endogenous Cytokines
Reverb Therapeutics, a leader in the emerging paradigm of redirecting endogenous cytokines as treatments for life-threatening diseases, debuts with seed financing led by founding investor Amplitude Ventures and participation from the Multiple Myeloma Research Foundation's venture philanthropy arm, the Myeloma Investment Fund.
AmplifierTM Platform for redirecting cytokines
"We are keenly aware of the clinical obstacles to more widespread use of exogenous cytokines to treat patients," said David de Graaf, Ph.D., Co-founder and CEO of Reverb Therapeutics. "Reverb's proprietary Amplifier antibodies utilize standard IgG frameworks along with advanced computational modeling and antibody engineering to build first-in-class novel therapeutics. The platform is designed to be modular and to use elements of existing and novel antibodies to redirect a given cytokine to a specific tumor, tissue or immune cell. It is broadly applicable across solid and liquid tumors and auto-immune diseases."
"We're excited by the potential of Reverb's Amplifier platform for the treatment of multiple myeloma," said Michael Andreini, President and CEO at the MMRF. "The emerging preclinical data suggest that this highly differentiated platform approach to cytkine therapy could be promising for myeloma patients."
"There is a lot of activity in the cytokine space," said Bharat Srinivasa, Principal at Amplitude and co-founder of Reverb. "Reverb's proprietary Amplifier platform stands out. It is elegant and straightforward, uniquely capable of using endogenous cytokine biology to create drugs with increased efficacy." Amplitude Ventures co-founded Reverb through its Pre-Amp venture studio program. As part of the financing, Bharat Srinivasa and Ali Tehrani, Partner at Amplitude, have joined Reverb's board of directors.
Founding team and SAB
The company is also supported by an outstanding scientific advisory board. The SAB includes:
Peter Sorger, D. Phil., Head of Therapeutic Sciences and Professor of Systems Biology at Harvard University;
About Reverb Therapeutics
About Amplitude Ventures
About the Myeloma Investment Fund